Essex (02487.HK) announced that its potential new drug CU-20401 (recombinant mutant collagenase) has obtained topline data from Phase II clinical trials conducted in China for the treatment of submental fat accumulation. The data shows that the clinical trial has met its primary endpoint, with results that are statistically significant and clinically meaningful.

The analysis results show that in terms of efficacy, the primary efficacy endpoint data demonstrates that both the low-dose CU-20401 group and the high-dose CU-20401 group have higher therapeutic efficacy rates than the placebo control group, and the differences in efficacy rates are statistically significant. Similar efficacy advantages are also shown in the secondary efficacy endpoint data. Overall, CU-20401 demonstrates significant and robust therapeutic advantages with good safety.